Maternal serum screening and 22q11.2 deletion syndrome
M. Begleiter,Molly M. Lund,Andrea M. Atherton,J. Buchholz,H. Ardinger
DOI: https://doi.org/10.1002/ajmg.a.31616
2007-02-15
Abstract:Second trimester maternal serum screening (MSS) is performed by measuring concentrations of alpha fetoprotein (AFP), unconjugated estriol (uE3), beta human gonadotropin (bhCG) and inhibin-A. This technology is commonly used to identify pregnancies at increased risk for trisomy 21, trisomy 18, open neural tube defects and most recently, steroid sulfatase deficiency ichthyosis, and the Smith–Lemli–Opitz Syndrome (Table I). We report here on, two children with the 22q11.2 deletion syndrome whose mothers both had MSS results consistent with an increased risk for trisomy 18. The first patient was a female infant transferred to our hospital for evaluation and management of multiple congenital anomalies. The child was born to a 24-year-old G II P II who had MSS with a 1 in 23 risk that the infant had trisomy 18. Following a normal level II ultrasound exam amniocentesis was declined. The child was born at 36 weeks gestation at less than the 10th centile for height, weight, and head circumference, with the following anomalies: overriding sutures, sclerocorneas, microphthalmia with colobomas, posteriorly rotated ears, bulbous nasal tip, imperforate anus, long fingers and postaxial polydactyly of the right hand and right foot. FISH probes documented the 22q11.2 deletion. The second childwasborn at 29weeks gestation to a gravida V para IV SAB I, 36-year-old woman who had MSS with a 1 in 40 risk of trisomy 18. An ultrasound at 20 weeks gestation was normal. A follow-up ultrasound 4 weeks later identified a congenital heart defect and an amniocentesis was done with normal results (46,XY). At birth he presented with an interrupted aortic arch type B, VSD, hypospadias, posteriorly rotated ears, and asymmetric crying facies. 22q11.2 FISH probe established the diagnosis. Approximately 1 in 200 women who have MSS will be positive for trisomy 18 [Yankowitz et al., 1998]. The incidence of 22q11.2 deletion has been reported to be between 1/4,000 [Wilson et al., 1994] and 1/ 6,395 [Devriendt et al., 1998]. If MSS for trisomy 18 was not also identifying fetuses at risk for 22q11.2 deletion syndrome, then the expected incidence of these two independent events occurring together would be between 1/800,000 and 1/1,279,000 screening tests. Given the small probability that these events would occur by chance, we suggest that MSS positive for trisomy 18 may also be identifying fetuses at risk for the 22q11.2 deletion. We therefore suggest that all pregnancies with